ACE1708 / Acepodia - LARVOL DELTA

Acepodia provides corporate update and unveils new preclinical allogeneic NK cell therapy pipeline candidates at BIO Digital 2020 (GlobeNewswire) - "Dr. Hsiao will present an overview of the company’s proprietary oNK cells, and lead candidate ACE1702. Dr. Hsiao will also provide insight into new initiatives the company is taking to expand its cell therapy portfolio, including data from preclinical studies of ACE1755…preclinical studies of ACE1975 and ACE1708, ACC-oNK cell therapy candidates for treatment of solid tumors and hematological malignancies targeting CD70 and PD-L1, respectively… ACE1702 and initiated its first US clinical trial site in the third quarter of 2020 with an expected data readout by the end of 2020…Acepodia expects IND clearance by the FDA for ACE1755 in the first quarter of 2021…Acepodia expects to initiate Phase 1 clinical trials of ACE1975 in 2021….ACE1708…IND clearance anticipated in 2021."

IND • New P1 trial • New trial • Preclinical • Oncology • Solid Tumor